Organon & Co. (OGN)
13.90
0.00 (0.00%)
USD |
NYSE |
Nov 20, 10:35
Organon Cash from Operations (Quarterly) : 370.00M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 370.00M |
| June 30, 2026 | 107.00M |
| March 31, 2026 | 225.00M |
| December 31, 2025 | 141.00M |
| September 30, 2025 | 264.00M |
| June 30, 2025 | 220.00M |
| March 31, 2025 | 75.00M |
| December 31, 2024 | 390.00M |
| September 30, 2024 | 141.00M |
| June 30, 2024 | 332.00M |
| March 31, 2024 | 76.00M |
| December 31, 2023 | 397.00M |
| September 30, 2023 | 261.00M |
| June 30, 2023 | 27.00M |
| Date | Value |
|---|---|
| March 31, 2023 | 114.00M |
| December 31, 2022 | 267.00M |
| September 30, 2022 | 317.00M |
| June 30, 2022 | 151.00M |
| March 31, 2022 | 123.00M |
| December 31, 2021 | 181.00M |
| September 30, 2021 | 70.00M |
| June 30, 2021 | 1.472B |
| March 31, 2021 | 735.00M |
| December 31, 2020 | 387.00M |
| September 30, 2020 | 331.00M |
| June 30, 2020 | 803.00M |
| March 31, 2020 | 666.00M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Viatris, Inc. | 899.40M |
| Pacira Biosciences, Inc. | 50.07M |
| ANI Pharmaceuticals, Inc. | 83.79M |
| Corcept Therapeutics, Inc. | 142.89M |
| Veru, Inc. | -5.467M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -44.00M |
| Cash from Financing (Quarterly) | -5.00M |
| Free Cash Flow | 735.00M |
| Free Cash Flow Per Share (Quarterly) | 1.197 |
| Free Cash Flow to Equity (Quarterly) | 325.00M |
| Free Cash Flow to Firm (Quarterly) | 396.10M |
| Free Cash Flow Yield | 20.13% |